Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 4 , Pages 292-298 , October 2007

Clinical diagnosis of dementia

  • Alain Robillard

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: (514) 252-3528; Fax: (514) 252-3529.

References 

  1. Chertkow H. Introduction: the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006. Alzheimers Dement. 2007;3:262–265
  2. Rockwood K, Bouchard RW, Camicioli R, Léger G. Toward a revision of criteria for the dementias. Alzheimers Dement. 2007;3:428–440
  3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed–revised. Washington, DC: American Psychiatric Association; 1987;
  5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944
  6. O’Connor DW, Blessed G, Cooper B, Jonker C, Morris JC, Presnell IB, et al. Cross-national interrater reliability of dementia diagnosis in the elderly and factors associated with disagreement. Neurology. 1996;47:1194–1199
  7. Graham JE, Rockwood K, Beattie BL, McDowell I, Eastwood R, Gauthier S. Standardization of the diagnosis of dementia in the Canadian Study of Health and Aging. Neuroepidemiology. 1996;15:246–256
  8. Larson EB, McCurry SM, Graves AB, Bowen JD, Rice MM, McCormick WC, et al. Standardization of the clinical diagnosis of the dementia syndrome and its subtypes in a cross-sectional study: the Ni-Hon-Sea experience. J Gerontol A Biol Sci Med Sci. 1998;53A:M313–M319
  9. Fratiglioni L, Grut M, Forsell Y, Viitanen M, Winblad B. Clinical diagnosis of Alzheimer’s disease and other dementias in a population survey: agreement and causes of disagreement in applying Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, criteria. Arch Neurol. 1992;49:927–2
  10. Farrer LA, Cupples LA, Blackburn S, Kiely DK, Auerbach S, Growdon JH, et al. Interrater agreement for diagnosis of Alzheimer’s disease: the MIRAGE study. Neurology. 1994;44:652–656
  11. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer’s disease: the National Institute of Mental Health Genetics Initiative. Arch Neurol. 1994;51:1198–1204
  12. Lopez OL, Litvan I, Catt KE, Stowe R, Klunk W, Kaufer DI, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology. 1999;53:1292–1299
  13. Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, et al. Research evaluation and diagnosis of probable Alzheimer’s disease over the last two decades: I. Neurology. 2000;55:1854–1862
  14. Forette F, Henry JF, Orgogozo JM, et al. Reliability of clinical criteria for the diagnosis of dementia: a longitudinal multicenter study. Arch Neurol. 1989;46:646–648
  15. Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer’s disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry. 1999;174:45–50
  16. Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer’s disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, spect, X-ray CT, and apo E4 in medial temporal lobe dementias—Oxford Project to Investigate Memory and Aging. Int Psychogeriatr. 1998;10:271–302
  17. Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, et al. Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc. 1999;47:564–569
  18. Wade JP, Mirsen TR, Hachinski VC, Fisman M, Lau C, Merskey H. The clinical diagnosis of Alzheimer’s disease. Arch Neurol. 1987;44:24–29
  19. Victoroff J, Mack WJ, Lyness SA, Chui HC. Multicenter clinicopathological correlation in dementia. Am J Psychiatry. 1995;152:1476–1484
  20. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, et al. Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch Neurol. 1994;51:888–895
  21. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease: Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease. N Engl J Med. 1998;338:506–511
  22. Klatka LA, Schiffer RB, Powers JM, Kazee AM. Incorrect diagnosis of Alzheimer’s disease: a clinicopathologic study. Arch Neurol. 1997;53:35–42
  23. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): part X—neuropathology confirmation of the clinical diagnosis of Alzheimer’s disease. Neurology. 1995;45:461–466
  24. Berg L, McKeel DW, Miller JP, Storandt M, Rubin EH, Morris JC, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer’s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326–335
  25. Massoud F, Devi G, Stern Y, Lawton A, Goldman JE, Liu Y, et al. A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia. Arch Neurol. 1999;56:1368–1373
  26. Salmon DP, Thomas RG, Pay MM, Booth A, Hofstetter CR, Thal LJ, et al. Alzheimer’s disease can be accurately diagnosed in very mildly impaired individuals. Neurology. 2002;59:1022–1028
  27. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–308
  28. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005;62:1160–1163
  29. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov. 2003;2:646–653
  30. Grundman M, Petersen RC, Ferris S, Thomas RG, Aisen PS, Bennett DA, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59–66
  31. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil in the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388
  32. Chertkow H, Nasreddine Z, Joanette Y, Drolet V, Kirk J, Massoud F, et al. Mild cognitive impairment and cognitive impairment, no dementia: part A, concept and diagnosis. Alzheimers Dement. 2007;3:266–282
  33. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699
  34. Rockwood K, Davis H, MacKnight C, Vandorpe R, Gauthier S, Guzman A, et al. The Consortium to Investigate Vascular Impairment of Cognition: methods and first findings. Can J Neurol Sci. 2003;30:237–243
  35. Gold G, Giannakopoulos P, Montes-Paixao Junior C, et al. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology. 1997;49:690–694
  36. Gold G, Bouras C, Canuto A, Bergallo Herrmenn FR, Hof P, Mayor PA, et al. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry. 2002;159:82–87
  37. Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10,NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. Stroke. 2000;31:2952–2957
  38. Cosentino SA, Jefferson AL, Carey M, Price CC, Davis-Garrett K, Swenson R, et al. The clinical diagnosis of vascular dementia: a comparison among four classification systems and a proposal for a new paradigm. Clin Neuropsychol. 2004;18:6–21
  39. Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, et al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol. 2000;57:191–196
  40. Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer’s disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry. 2004;75:61–71
  41. Tierney MC, Black SE, Szalai JP, Snow WG, Fisher RH, Nadon G, et al. Recognition memory and verbal fluency differentiate probable Alzheimer disease from subcortical ischemic vascular dementia. Arch Neurol. 2001;58:1654–1659
  42. McKeith G, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863–1872
  43. Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y. Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord. 2004;19:60–67
  44. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. SIC Task Force Appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord. 2003;18:467–486
  45. Kosaka K. Lewy bodies in cerebral cortex: report of three cases. Acta Neuropathol. 1978;42:127–134
  46. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree: a new disease?. Clin Neuropathol. 1984;3:185–192
  47. Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55:969–978
  48. Luis CA, Barker WW, Gajaraj K, Harwood D, Petersen R, Kashuba A, et al. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry. 1999;14:526–533
  49. Mega MS, Masterman DL, Benson DF, Vinters HV. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology. 1996;47:1403–1409
  50. Verghese J, Crystal HA, Dickson DW, Lipton RB. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology. 1999;53:1974–1982
  51. Lopez OL, Becker JT, Kaufer D, Hamilton R, Sweet R, Klunk W, et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol. 2002;59:43–46
  52. Lopez OL, Hamilton RL, Becker JT, Wisniewski S, Kaufer DI, DeKosky ST. Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies. Neurology. 2000;54:1780–1787
  53. Del Ser T, Hachinski V, Merskey H, Munoz DG. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord. 2001;15:31–44
  54. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003;60:1586–1590
  55. Hodges JR. Frontotemporal dementia (Pick’s disease): clinical features and assessment. Neurology. 2001;56(Suppl 4):S6–S10
  56. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994;57:416–418
  57. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–1554
  58. Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1999;66:184–188
  59. Miller BL, Ikonte C, Ponton M, Levy M, Boone K, Darby A, et al. A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations. Neurology. 1997;48:937–942
  60. Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwell JL, Duffy JR, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;66:41–48
  61. Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure: observations on cerebrospinal fluid hydrodynamics. J Neurol Sci. 1965;2:307–327
  62. Vanneste JA. Three decades of normal pressure hydrocephalus: are we wiser now?. J Neurol Neurosurg Psychiatry. 1994;57:1021–1025
  63. Vanneste J, Augustijn P, Dirven C, Tan WF, Goedhart ZD. Shunting normal-pressure hydrocephalus: do the benefits outweigh the risks?. Neurology. 1992;42:54–58
  64. Walchenbach GE, Thomeer RT, Vanneste JA. The value of temporary external lumbar CSF drainage in predicting the outcome of shunting on normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry. 2002;72:503–506
  65. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer’s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2003;2:506–511
  66. Silverberg GD, Heit G, Huhn S, Jaffe RA, Chang SD, Bronte-Stewart H, et al. CSF production is reduced in dementia of the Alzheimer’s type. Neurology. 2001;57:1763–1766
  67. Silverberg GD, Levinthal E, Sullivan EV, Bloch DA, Chang SD, Leverenz J, et al. Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study. Neurology. 2002;59:1139–1145
  68. Masters CL, Harris JO, Gajdusek DC, Gibbs CJ, Bernoulli C, Asher DM. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol. 1979;5:177–188
  69. Cathala F, Brown P, Castaigne P, Gajdusek DC. La maladie de Creutzfeldt-Jakob en France continentale: etude rétrospective de 1968–1977. Rev Neurol. 1979;5:439–454
  70. Concerted action of the EU. Surveillance of Creutzfeldt-Jakob disease in the European community: minutes of the second meeting in Rome, July 3, 1993, and the third meeting in Paris, April 29–30. 1994;
  71. Poser S, Mollenhauer B, Kraubeta A, Zerr I, Steinhoff BJ, Schroeter A, et al. How to improve the clinical diagnosis of Creutzfeldt–Jakob disease. Brain. 1999;122:2345–2351
  72. Brandel JP, Delasnerie-Laupretre N, Laplanche JL, Hauw JJ, Alperovitch A. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology. 2000;54:1095–1099
  73. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med. 1996;335:924–930
  74. Burkhard PR, Sanchez JC, Landis T, Hochstrasser D. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology. 1997;56:1528–1533
  75. Castellani RJ, Colucci M, Xie Z, Zou W, Li C, Parchi P, et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology. 2004;63:436–442
  76. Shiga Y, Miyazawa K, Sato S, Fukushima R, Shibuya S, Sato Y, et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology. 2004;63:443–449
  77. Meissner B, Köhler K, Körtner K, Bartl M, Jastrow U, Mollenhauer B, et al. Sporadic Creutzfeldt-Jakob disease: magnetic resonance imaging and clinical findings. Neurology. 2004;63:450–456

PII: S1552-5260(07)00567-5

doi: 10.1016/j.jalz.2007.08.002

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 4 , Pages 292-298 , October 2007

Article Tools